MediPharm Labs Management

Management criteria checks 3/4

MediPharm Labs' CEO is David Pidduck, appointed in Apr 2022, has a tenure of 2.58 years. total yearly compensation is CA$1.31M, comprised of 36% salary and 64% bonuses, including company stock and options. directly owns 4.08% of the company’s shares, worth €735.25K. The average tenure of the management team and the board of directors is 5.1 years and 5.4 years respectively.

Key information

David Pidduck

Chief executive officer

CA$1.3m

Total compensation

CEO salary percentage	36.0%
CEO tenure	2.6yrs
CEO ownership	4.1%
Management average tenure	5.1yrs
Board average tenure	5.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Pidduck's remuneration changed compared to MediPharm Labs's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-CA$12m
Jun 30 2024	n/a	n/a	-CA$13m
Mar 31 2024	n/a	n/a	-CA$14m
Dec 31 2023	CA$1m	CA$470k	-CA$13m
Sep 30 2023	n/a	n/a	-CA$16m
Jun 30 2023	n/a	n/a	-CA$20m
Mar 31 2023	n/a	n/a	-CA$26m
Dec 31 2022	CA$3m	CA$315k	-CA$30m

Compensation vs Market: David's total compensation ($USD930.25K) is above average for companies of similar size in the German market ($USD474.54K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Pidduck

2.6yrs

Tenure

CA$1,305,051

Compensation

Mr. David A. Pidduck is Chief Executive Officer and Director at MediPharm Labs Corp. since April 20, 2022. Mr. Pidduck has been the Chief Executive Officer and President of Purdue Pharma Inc. since Septemb...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Pidduck	CEO & Director	2.6yrs	CA$1.31m	4.08% € 735.3k
Keith Strachan	Co-Founder & President	5.8yrs	CA$819.48k	2.17% € 390.7k
Greg Hunter	Chief Financial Officer	3.8yrs	CA$957.75k	0.31% € 56.6k
Patrick McCutcheon	Founder	9.8yrs	CA$858.16k	no data
Brett Moon	Vice President of Sales	4.5yrs	no data	no data
Kirk Binns	Executive Vice President of Global Accounts	5.8yrs	no data	no data

5.1yrs

Average Tenure

Experienced Management: MLZ's management team is seasoned and experienced (5.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Pidduck	CEO & Director	2.6yrs	CA$1.31m	4.08% € 735.3k
Shelley Martin	Independent Director	4.4yrs	CA$64.49k	0.020% € 3.5k
Michael Bumby	Independent Director	1.6yrs	CA$34.45k	0.050% € 9.0k
Christopher Taves	Independent Chairman of the Board	4.3yrs	CA$87.14k	0.35% € 62.3k
Miriam McDonald	Member of the Science Advisory Board	5.6yrs	CA$32.40k	no data
Leslie Brown	Member of the Science Advisory Board	5.6yrs	no data	no data
Matt Archibald	Member of the Science Advisory Board	5.6yrs	no data	no data
Markus Roggen	Member of the Science Advisory Board	5.6yrs	no data	no data
Arshad Hack	Member of the Science Advisory Board	5.6yrs	no data	no data
Jerry King	Member of the Science Advisory Board	5.6yrs	no data	no data
Carolina Landolt-Marticorena	Member of the Science Advisory Board	5.3yrs	no data	no data
Christopher Halyk	Independent Director	4.3yrs	CA$56.05k	0.043% € 7.7k

5.4yrs

Average Tenure

Experienced Board: MLZ's board of directors are considered experienced (5.4 years average tenure).

MediPharm Labs Management

Management criteria checks 3/4

Key information

Recent management updates

MediPharm Labs Corp. Announces Executive Changes

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

High number of new and inexperienced directors

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

Recent updates

Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023)

MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024

MediPharm Labs Corp. Announces Executive Changes

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 2Q 2023)

MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.01 loss in 1Q 2023)

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: CA$0.04 loss per share (vs CA$0.11 loss in FY 2022)

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022)

New minor risk - Profitability

Forecast to breakeven in 2024

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 2Q 2022)

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 1Q 2022)

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.03 loss in 3Q 2021)

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 2Q 2021)

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.07 loss in 1Q 2021)

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Full year 2021 earnings released: CA$0.22 loss per share (vs CA$0.48 loss in FY 2020)

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold €60k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Founder & Chairman of the Board recently sold €329k worth of stock

Independent Director recently bought €206k worth of stock

MediPharm Labs Launches High-CBD Wellness Oils in Quebec

First quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.13 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.48 loss per share (vs CA$0.014 profit in FY 2019)

MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

Independent Director recently bought €132k worth of stock

Medipharm Labs Corp. Announces Plan to Launch New Over-The-Counter Products

MediPharm Labs Corp. has completed a Composite Units Offering in the amount of CAD 29 million.

Interim Chief Financial Officer has left the company

New 90-day high: €0.57

MediPharm Labs Corp. Appoints Greg Hunter as Chief Financial Officer, Effective February 8, 2021

MediPharm Labs Appoints Warren Everitt to Board of Directors

MediPharm Labs Corp. Enters a Supply Agreement with Nova Scotia Liquor Corporation

New 90-day low: €0.32

MediPharm Labs Corp. Announces Executive Changes

Revenue misses expectations

Third quarter 2020 earnings released: CA$0.11 loss per share

New 90-day low: €0.47